ICNMDigital 2023


icnmdigital 2023

Video on Demand*

* Login required


The first scientific session at ICNMDigital 2023 (Muscle Disorders) included presentations on effects of treatment in infantile-onset and late-onset Pompe disease (Dr. Nadine Van der Beek), on emerging therapeutic options in various subtypes of myositis (Andrew Mammen), and on recognition and causes of rhabdomyolysis (Prof. Benedikt Schoser).

In the session on Peripheral Neuropathies, Dr. Jeffrey Allen presented on new classification of CIDP and variants no longer included; Dr. Roser Velasco spoke on immunotherapy and checkpoint inhibitors-related neuropathies; while Prof. Teresa Coelho focused on amyloid associated neuropathies, esp. hATTR.

In the Neuromuscular Junction Disorders session, Dr. Carolina Barnett-Tapia highlighted patient assessment methods in myasthenia gravis, Prof. Vera Bril provided an update on treatment of MG, and Prof. Jan Verschuuren updated us on LEMS.

The final scientific session addressed the current state of our understanding of ALS genetics (Dr. Eva Feldman), utility of disease biomarkers (Prof. Philip Van Damme), approach to drug treatment (Dr. Stephen Goutman), and palliative care (Prof. Orla Hardiman).

In addition to these scientific sessions, five industry-supported symposia addressed new strategies for advancing care and protecting bone health in duchenne muscular dystrophy (Santhera), aging and infectious diseases in myasthenia gravis (Grifols), limb-girdle muscular dystrophies (Sarepta), continuity of care and totality of evidence in nmDMD (PTC), and latest learnings about zolgensma treatment in SMA (Novartis). A presentation by PTC on the journey of boys with nonsense mutation Duchenne muscular dystrophy rounded up this virtual event.


ICNMDigital2023 logoPlanning & Program Committee

  • Prof. P. James B. Dyck (Chair)
  • Prof. Wolfgang Grisold
  • Prof. Gauthier Remiche
  • Prof. Marianne de Visser
  • Prof. Vera Bril
  • Dr. Eva Feldman
  • Prof. Gil Wolfe


Day 1 Day 2
Muscle Disorders Neuromuscular Junction Disorders

Peripheral Neuropathies

Motor Neuron Diseases

Industry-Supported Symposium

  • From Clinical Trials to Clinical Practice: What Have We Learnt About Zolgensma (Onasemnogene Abeparvovec) Treatment in SMA?
  • Navigating the Changing Disease Landscape: Continuity of Care and the Totality of Evidence in nmDMD
  • Limb-Girdle Muscular Dystrophies: Clinical Course of Disease and Advances in Gene Therapy Development

Industry-Supported Symposium

  • Aging and Infectious Diseases in Myasthenia Gravis
  • New Strategies for Advancing Care and Protecting Bone Health in Duchenne Muscular Dystrophy